neflamapimod — Topline data
H2 2026
CervoMed expects to report topline data from its Phase 2a RESTORE trial evaluating neflamapimod in patients recovering from acute ischemic stroke in the second half of 2026.Source filing
CRVO biotech catalysts & pipeline
CERVOMED INC · Data as of 2026-10-25
Upcoming catalysts
neflamapimod — Topline data
Q1 2027
"We look forward to presenting 24-week biomarker data at the Clinical Trials on Alzheimer's Disease conference in November, followed by topline clinical data in the first quarter of 2027."Source filing
neflamapimod — Initial data
Q1 2027
We look forward to sharing the first biomarker data with neflamapimod in patients with nfvPPA early in the fourth quarter of 2026 and the first clinical data in the first quarter of 2027.Source filing
neflamapimod — Conference presentation
Nov 16
Date/Time: Monday, November 16 (2:00 p.m. ET) – Tuesday, November 17 (5:30 p.m. ET)Source filing
neflamapimod — Conference presentation
Nov 16–Nov 19
Full 12-week and initial, 24-week biomarker data from the trial will be presented at the 19th CTAD conference, taking place November 16-19, 2026, in Boston, Massachusetts.Source filing